Stay updated with breaking news from Randomized Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib
Program details on keynote addresses, distinguished awards and late-breaking abstracts are being provided by program planners of the American Society for Radiation Oncology (ASTRO) Annual Meeting, set for October 23-26, in San Antonio, TX.
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
-- Full data support the potential of obicetrapib to address unmet medical need for millions of patients who cannot achieve their LDL-C targets with high-intensity statin therapy (HIS) alone -- -- Treatment
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least